Veracyte, Inc. (VCYT)
NASDAQ: VCYT · Real-Time Price · USD
43.96
+0.84 (1.94%)
Oct 19, 2026, 10:58 AM EDT - Market open
Veracyte Revenue
Veracyte had revenue of $150.32M in the quarter ending June 30, 2026, with 15.49% growth. This brings the company's total for the last twelve months to $561.90M, up 17.28% year-over-year. In the year 2025, Veracyte had annual revenue of $517.15M with 16.01% growth. That makes Veracyte the 10,582nd largest company in the world by revenue and 2,227th in the United States.
Revenue (ttm)
$561.90M
Revenue Growth
+17.28%
P/S Ratio
6.17
Revenue / Employee
$744,238
Employees
755
Market Cap
3.53B
Revenue by Geography
- United States 496.60M 96.0%
- International 20.55M 4.0%
Fiscal year ended Dec 31, 2025 See the full Veracyte breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 517.15M | 71.38M | 16.01% |
| Dec 31, 2024 | 445.76M | 84.71M | 23.46% |
| Dec 31, 2023 | 361.05M | 64.52M | 21.76% |
| Dec 31, 2022 | 296.54M | 77.02M | 35.09% |
| Dec 31, 2021 | 219.51M | 102.03M | 86.85% |
| Dec 31, 2020 | 117.48M | -2.89M | -2.40% |
| Dec 31, 2019 | 120.37M | 28.36M | 30.82% |
| Dec 31, 2018 | 92.01M | 20.06M | 27.87% |
| Dec 31, 2017 | 71.95M | 6.87M | 10.55% |
| Dec 31, 2016 | 65.09M | 15.58M | 31.48% |
| Dec 31, 2015 | 49.50M | 11.31M | 29.62% |
| Dec 31, 2014 | 38.19M | 16.31M | 74.51% |
| Dec 31, 2013 | 21.88M | 10.26M | 88.20% |
| Dec 31, 2012 | 11.63M | 8.98M | 339.62% |
| Dec 31, 2011 | 2.65M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| RadNet | 2.27B |
| Qiagen | 2.10B |
| Sotera Health Company | 1.22B |
| NeoGenomics | 766.30M |
| CareDx | 458.09M |
| GeneDx Holdings | 454.43M |
| BillionToOne | 397.41M |
| Adaptive Biotechnologies | 308.08M |
VCYT News
- 3 hours ago - Six Studies to Highlight Veracyte's Genomic Tests Across Breast, Prostate and Bladder Cancer at ESMO 2026 - GlobeNewsWire
- 3 days ago - Veracyte Secures Medicare Reimbursement for Prosigna Breast Risk of Recurrence Test - GlobeNewsWire
- 4 days ago - Veracyte to Release Third Quarter 2026 Financial Results on November 4, 2026 - GlobeNewsWire
- 13 days ago - Cathie Wood’s ARK Investment buys 115.5K shares of Veracyte today - TheFly
- 17 days ago - Cathie Wood’s ARK Investment buys 159K shares of Veracyte today - TheFly
- 20 days ago - Veracyte announces new findings from Phase III NRG/RTOG 0815 trial - TheFly
- 20 days ago - Phase III Trial Demonstrates Veracyte's Decipher Prostate Test Predicts Benefit from Adding Hormone Therapy to Radiation - GlobeNewsWire
- 23 days ago - Veracyte Announces Eight Decipher-Focused Studies to Be Presented at ASTRO 2026 - GlobeNewsWire